Key facts
- This page summarizes Ph.D. Ronald A. Pepin's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2025, 16:06.
Ph.D. Ronald A. Pepin - 15 Dec 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- SR. VP & CBO
- Issuer ticker
- CLDX
- Reported as of
- 15 Dec 2025
- Net transaction value
- +$105,714
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2025, 16:06:34 UTC
- Prior SEC filing
- 09 Jun 2025
- Next SEC filing
- 29 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Ronald A. Pepin, Ph.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Ronald A. Pepin filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 17 Dec 2025.
Change
- Previous filing in this sequence was filed on 09 Jun 2025.
- Current net transaction value: +$105,714.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001214504
Primary reporting owner
PEPIN RONALD
- Relationship
- SR. VP & CBO
- Address
- C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON
- Signature
- /s/ Sam Martin, attorney-in-fact for Ronald A. Pepin, Ph.D.
- Signature date
- 17 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $75,134
- Shares
- +8,333
- Change %
- +1091%
- Price
- $9.02
- Shares after
- 9,097
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $30,580
- Shares
- +11,000
- Change %
- +121%
- Price
- $2.78
- Shares after
- 20,097
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,333
- Change %
- -62%
- Price
- $0.000000
- Shares after
- 5,000
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,333
- Exercise price
- $9.02
- Footnotes
- F1, F3
CLDX
transaction
Derivative
Incentive Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -11,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,000
- Exercise price
- $2.78
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
Footnote F2
Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
Footnote F3
As of June 13, 2022, the option is fully vested.
Footnote F4
As of June 19, 2023, the option is fully vested.